English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

pharmacodynamics of TOP1288, a Narrow Spectrum Kinase Inhibitor, delivered topically to the colon via oral administration Adele Rowley1, Mike Taylor1, Ajay Duggal1 Martyn Foster1, Sameer Sirohi1, Yemisi Solanke1, Claire Walshe1, Matthew Fyfe1, Steve Webber1, Simon Travis2 1Topivert Pharma Ltd, London, United Kingdom, 2Oxford University Hospitals Trust, Translational Gastroenterology Unit, Oxford, United Kingdom

journal of crohn's and colitis

P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration